Class information for:
Level 1: ESSENTIAL THROMBOCYTHEMIA//POLYCYTHEMIA VERA//MYELOFIBROSIS

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
151 4065 37.5 78%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
1619 6500 ESSENTIAL THROMBOCYTHEMIA//POLYCYTHEMIA VERA//MYELOFIBROSIS

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ESSENTIAL THROMBOCYTHEMIA Author keyword 667 74% 12% 495
2 POLYCYTHEMIA VERA Author keyword 489 66% 11% 450
3 MYELOFIBROSIS Author keyword 342 56% 10% 414
4 MYELOPROLIFERATIVE NEOPLASMS Author keyword 251 74% 5% 184
5 PRIMARY MYELOFIBROSIS Author keyword 188 78% 3% 123
6 MYELOPROLIFERATIVE DISORDERS Author keyword 168 54% 5% 218
7 JAK2V617F Author keyword 150 80% 2% 93
8 ESSENTIAL THROMBOCYTHAEMIA Author keyword 150 70% 3% 125
9 ANAGRELIDE Author keyword 143 79% 2% 91
10 IDIOPATHIC MYELOFIBROSIS Author keyword 119 71% 2% 96

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 ESSENTIAL THROMBOCYTHEMIA 667 74% 12% 495 Search ESSENTIAL+THROMBOCYTHEMIA Search ESSENTIAL+THROMBOCYTHEMIA
2 POLYCYTHEMIA VERA 489 66% 11% 450 Search POLYCYTHEMIA+VERA Search POLYCYTHEMIA+VERA
3 MYELOFIBROSIS 342 56% 10% 414 Search MYELOFIBROSIS Search MYELOFIBROSIS
4 MYELOPROLIFERATIVE NEOPLASMS 251 74% 5% 184 Search MYELOPROLIFERATIVE+NEOPLASMS Search MYELOPROLIFERATIVE+NEOPLASMS
5 PRIMARY MYELOFIBROSIS 188 78% 3% 123 Search PRIMARY+MYELOFIBROSIS Search PRIMARY+MYELOFIBROSIS
6 MYELOPROLIFERATIVE DISORDERS 168 54% 5% 218 Search MYELOPROLIFERATIVE+DISORDERS Search MYELOPROLIFERATIVE+DISORDERS
7 JAK2V617F 150 80% 2% 93 Search JAK2V617F Search JAK2V617F
8 ESSENTIAL THROMBOCYTHAEMIA 150 70% 3% 125 Search ESSENTIAL+THROMBOCYTHAEMIA Search ESSENTIAL+THROMBOCYTHAEMIA
9 ANAGRELIDE 143 79% 2% 91 Search ANAGRELIDE Search ANAGRELIDE
10 IDIOPATHIC MYELOFIBROSIS 119 71% 2% 96 Search IDIOPATHIC+MYELOFIBROSIS Search IDIOPATHIC+MYELOFIBROSIS

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of publ.
in class
1 POLYCYTHEMIA VERA 1509 60% 40% 1633
2 ESSENTIAL THROMBOCYTHEMIA 1168 66% 27% 1089
3 TYROSINE KINASE JAK2 782 71% 15% 630
4 MYELOID METAPLASIA 598 68% 13% 532
5 CHRONIC MYELOPROLIFERATIVE DISORDERS 505 71% 10% 403
6 MYELOPROLIFERATIVE DISORDERS 456 43% 20% 799
7 IDIOPATHIC MYELOFIBROSIS 333 66% 8% 308
8 AGNOGENIC MYELOID METAPLASIA 328 70% 7% 270
9 RISK ESSENTIAL THROMBOCYTHEMIA 272 98% 2% 65
10 MYELOFIBROSIS 271 45% 11% 452

Journals


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CURRENT HEMATOLOGIC MALIGNANCY REPORTS 3 10% 1% 24

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
CME Information: Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification, and management 2015 8 94 88%
Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms 2008 437 72 63%
Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies 2011 112 80 89%
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 2010 205 127 61%
An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms 2014 35 31 58%
Medical progress: Myelofibrosis with myeloid metaplasia. 2000 388 74 73%
New mutations and pathogenesis of myeloproliferative neoplasms 2011 135 167 56%
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond 2011 100 137 69%
Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation 2004 158 83 86%
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders 2007 222 90 61%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 HEMATOL BLOOD COAGULAT 52 68% 1.1% 46
2 STUDY MYELOFIBROSIS 46 71% 0.9% 37
3 CONGIUNTO MMPC 17 100% 0.2% 8
4 THROMBOCYTHEMIA VERA STUDY GRP 14 100% 0.2% 7
5 MYELOPROLIFERAT DISORDERS CONSORTIUM 12 86% 0.1% 6
6 EUROPEAN WORKING GRP MYELOPROLIFERAT DISORDERS 11 100% 0.1% 6
7 GOODHEART 10 61% 0.3% 11
8 LEUKEMIA SERV 10 19% 1.1% 45
9 UNIT CLIN IMMUNOL IMMUNOHEMATOL TRANSFUS SERV 9 83% 0.1% 5
10 CATTEDRA UO EMATOL 8 62% 0.2% 8

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000258773 AUTOIMMUNE MYELOFIBROSIS//DACRYOCYTES//ABNORMAL LOCALIZATION OF IMMATURE PRECURSORS ALIP
2 0.0000119888 CHRONIC NEUTROPHILIC LEUKEMIA//CHRONIC NEUTROPHILIC LEUKAEMIA//COLONY STIMULATING FACTOR 3 RECEPTOR MUTATION
3 0.0000104959 ERYTHROMELALGIA//ERYTHERMALGIA//SECONDARY ERYTHERMALGIA
4 0.0000089552 TOFACITINIB//JAK3//CP 690 550
5 0.0000085545 FREE FLOATING THROMBUS//CAROTID ARTERY THROMBUS//EXTREME THROMBOCYTOSIS
6 0.0000072841 EXTRAMEDULLARY HEMATOPOIESIS//EXTRAMEDULLARY HAEMATOPOIESIS//EXTRAMEDULLARY HAEMOPOIESIS
7 0.0000063744 HYDROXYUREA//GENET HUMAN THER Y//TARGET CELL AVAILABILITY
8 0.0000052908 TUMOR CLONALITY//CLONAL REMISSION//M27 BETA
9 0.0000046038 THROMBOPOIETIN//C MPL//MEGAKARYOCYTE
10 0.0000043489 ACQUIRED VON WILLEBRAND SYNDROME//ACQUIRED VON WILLEBRAND DISEASE//ACQUIRED VON WILLEBRANDS SYNDROME